Gebruikte literatuur Arshad SH, Bateman B, Matthews SM. Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study. Thorax 2003;58:489-493 Bakker W, Dijkman JH. Rhonchi en crepitaties: nomenclatuur en interpretatie. Ned Tijdschr Geneeskd 1990;134:477-80. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167(6):813-8. Bateman ED. Overall asthma control: The relationship between current control and future risk. J Allergy Clin Immunol 2010;125:600-8. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax published online November 23, 2010. Berg JD van der. Bronchiale provocatietests en astma. NTvA 2008,8:76-81. Boomsma LJ, Van Horssen N, Verduijn MM, Dijkers FW, Heijboer-Vinks IC, Brunninkhuis WJM, De Haan-Gouw PPT, Kwint HF, Grol MH, Lelie-van der Zande ACAM, Flikweert S. Landelijke Eerstelijns Samenwerkings Afspraak Chronische medicatie bij astma/copd en diabetes mellitus type 2. Huisarts Wet 2006:49(10):511-5. Boulet LP. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Canadian Respir J 2002;9(6):417-23. Bousquet J, Mantzouranis E et al. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010 Oct 4. [Epub ahead of print] British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma (2005). www.sign.ac. uk/guidelines/fulltext/63/update2005.html. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma (2005). www.sign.ac.uk/guidelines/fulltext/63/update2005.html. Busse WW, RF Lemanske Jr, JE Green. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010;376:826-834. dr. J.C.C.M. in t Veen, dr. N.H. Chavannes, Het Astma Formularium, DOI 10.1007/978-90-313-8641-3, 2011 Bohn Stafleu van Loghum, onderdeel van Springer Media
Gebruikte literatuur 83 Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003 Aug;58(8):659-64. Castro M et al. Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma A Multicenter, Randomized, Double- Blind, Sham-Controlled Clinical Trial. Am J Respir Crit Care Med 2010; 181:116-124. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006;CD000052. Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2004; CD000364. CBO Richtlijn Behandeling van Tabaksverslaving. Herziening 2009. Chavannes NH et al. NHG-Standaard Stoppen met roken. Huisarts en Wetenschap 2007;7:306-314. Chavannes NH, Schermer TR, Wouters EF, Akkermans RP, Dekhuijzen RP, Muris JW, van Weel C, van Schayck CP. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. Int J Chron Obs Pulm Dis 2009;4:431-436. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting betaagonists in the treatment of asthma. N Engl J Med, 2010 Apr 1;362(13): 1169-71. Corren J. Small airways disease in asthma. Curr Allergy Asthma Rep 2008; 8:533-9. Cunnington D et al. Oral versus intravenous corticosteroids in adults hospitalised with acute asthma. Pulm Pharmacol Ther. 2005;18:207-12. Dekhuijzen PNR, De standaard Astma bij volwassenen (tweede herziening) van het Nederlands Huisartsen Genootschap; reactie vanuit de pulmonologie. Ned Tijdschr Geneeskd 2008;152:1138-40. Djukanović R, Wilson SJ, et al. Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respir Med 2010 Oct; 104(10):1425-35. Epub 2010 Aug 14. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006;CD003137. Etminnan M. Acetaminophen use and the risk of asthma in children and adults. Chest 2009:136. Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1076-82.
84 Het Astma Formularium Geijer RMM, Chavannes NH, Muris JWM, Sachs APE, Schermer T, Smeele IJM, Thoonen B, Van der Molen T, Van Schayck CP, Van Weel C, Kolnaar BGM, Grol MH. Huisarts Wet 2007;50(11):537-51. Gelfand EW, Kraft M. The importance and features of the distal airways in children and adults. J Allergy Clin Immunol 2009;124(6 Suppl):S84-7. Gibson PG, Powell H, Wilson A, Abramson MJ, Haywood P, Bauman A, Hensley MJ, Walters EH, Roberts JJL. Selfmanagement education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD001117. DOI: 10.1002/ 14651858.CD001117. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009 Aug;64(8): 728-35. Gilliland FD, Islam T, Berhane K, Gauderman WJ, McConnell R, Avol E, et al. Regular smoking and asthma incidence in adolescents. Am J Respir Crit Care Med 2006;174:1094-100. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. (2009). www.ginasthma.com. Gotzsche PC, Krogh Johansen H. House dust mite control measures for asthma. Cochrane Database of Systematic Reviews 2008;2. Art. No.: CD001187. Green RH, Brightling CE, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002 Nov 30; 360(9347):1715-21. Haldar et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. New Eng J Med 2009;360:973. Hansel TT, Tennant RC, Tan AJ, Higgins LA, Neighbour H, Erin EM, Barnes PJ. Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease. Drugs Today (Barc) 2004 Jan; 40(1):55-69. Ho ANH et al. Heliox vs Air-Oxygen Mixtures for the Treatment of Patients With Acute Asthma : A Systematic Overview. Chest 2003;123: 882. Hughes R et al. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet 2003;361:2114. Huisstede A van, Braunstahl GJ. Systemische inflammatie bij obesitas en astma. NTvA 2010: in press. in t Veen. Astma en de rol van de kleine luchtwegen: een hernieuwde interesse met consequenties voor de praktijk. NTvA 2011, in press. in t Veen 2010, NTvA in press. Kress JP. The Utility of Albuterol Nebulized with Heliox during Acute Asthma Exacerbations. Amer J Resp Crit Care Med 2002;165:1317.
Gebruikte literatuur 85 Kuna P, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61(5):725-736. Lazarus SC. Emergency treatment of asthma. N Engl J Med, 2010 Aug 19; 363(8):755-64. Lazarus SC, Chinchilli VM, et al. National Heart Lung and Blood Institute s Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007 Apr 15;175(8):783-90. LESA: Landelijke Eerstelijns Samenwerkings Afspraak Chronische medicatie bij astma/copd en diabetes mellitus type 2. Boomsma LJ, Van Horssen N, Verduijn MM, Dijkers FW, Heijboer-Vinks IC, Brunninkhuis WJM et al. Huisarts Wet 2006:49(10):511-5. Long Alliantie Nederland. Zorgstandaard COPD, 2010. Lougheed MD. Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada. Can Respir J 2010:17;57-60. Meer V van der, Bakker MJ, van den Hout WB, Rabe KF, Sterk PJ, Kievit J, Assendelft WJ, Sont JK; SMASHING (Self-Management in Asthma Supported by Hospitals, ICT, Nurses and General Practitioners) Study Group. Internet-based self-management plus education compared with usual care in asthma: a randomized trial. Ann Intern Med 2009 Jul 21;151(2):110-20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. Morgan WJ, Crain EF, Gruchalla RS, O Connor GT, Kattan M, Evans R III, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004;351:1068-80. Nair P et al. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. New Eng J Med 2009:360:985. Nederlandse Longstichting. Longziekten Feiten en Cijfers 2008. Nieuwenhof L. van den. Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study. Family Practice 2006;23;674-81. NVALT Richtlijn Acuut ernstig Astma, 2004. Palen J van der, Klein JJ, Van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034-7. Peters SP et al. Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. NEJM ahead op publ. Postma DS, Koppelman GH. Genetics of asthma: where are we and where do we go? Proc Am Thorac Soc 2009 May 1;6(3):283-7. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2004;CD004109.
86 Het Astma Formularium Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40. Roberts G, Newsom D, Gomez K, Raffles A, Saglani S, Begent J, Lachman P, Sloper K, Buchdahl R, Habel A; North West Thames Asthma Study Group. Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. Thorax 2003;58(4):306-10. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001;CD002178. Schayk CP van, et al. Is there any role for allergen avoidance in the primary prevention of childhood asthma? J Allergy Clin Immunol 2007; 119;1323. Schermer TR, Thoonen BP, Van den Boom G, Akkermans RP, Grol RP, Folgering HT, et al. Randomized controlled economic evaluation of asthma self-management in primary health care. Am J Respir Crit Care Med 2002;166:1062-72. Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999 Apr; 159(4 Pt 1):1043-51. Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006;CD004108. Szefler SJ, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial Lancet 2008;372:1065. Venables KM, Chan-Yeung M. Occupational asthma. Lancet 1997;349: 1465. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2004;CD003559. Weatherall M et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;34:812-818. Weatherall M, M Wijesinghe, K Perrin, M Harwood, R Beasley. Metaanalysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43. Wenzel S. Pathology of difficult asthma. Paediatr Respir Rev 2003;4:306-11.
Gebruikte literatuur 87 Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13. Wijnhoven HAH et al. De helft van de astmapatiënten heeft onvoldoende ziektecontrole H&W. 2006;49:398. www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm200776.htm www.goldcopd.com www.nhg.org: rubriek patiëntenvoorlichting. www.spirxpert.com Zantinge EM, Deville WJJM, Heijmans MJWM. Allochtonen met astma, COPD of hooikoorts in Nederland: wat is er bekend? Utrecht: NIVEL, 2006.
Geneesmiddelenoverzicht Bron: Gebaseerd op Farmacotherapeutisch Kompas online beclomethason: BECLOMETASON DOSISAËROSOL/INHALA- TIEPOEDER [Diverse fabrikanten] (dipropionaat) (Dosisaërosol CFK-vrij Inhalator 50 microg/dosis; 200 doses. Dosisaërosol CFK-vrij Inhalator 100 microg/dosis; 200 doses. Dosisaërosol CFK-vrij Inhalator 250 microg/dosis; 200 doses. Inhalatiepoeder in patroon Cyclocaps 100 microg, 200 microg, 400 microg); QVAR [IVAX Farma bv] ((dipropionaat) Dosisaërosol Extrafijn CFK-vrij Inhalator 50 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Aerochamber plus met masker 50 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Aerochamber plus met mondstuk 50 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Inhalator 100 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Aerochamber plus met mondstuk 100 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Aerochamber plus met masker 100 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Autohaler 50 microg/dosis; 200 doses. Dosisaërosol Extrafijn CFK-vrij Autohaler 100 microg/dosis; 200 doses) beclomethason/formoterol: FOSTER [Chiesi Pharmaceuticals bv] (Dosisaërosol 100/6 ; 120 doses. Bevat per dosis formoterol(fumaraat) 6 microg, beclometason(dipropionaat) 100 microg) budesonide: BUDESONIDE DOSISAËROSOL/INHALATIEPOE- DER [Diverse fabrikanten] (Dosisaërosol CFK-vrij 200 microg/ dosis; 200 doses. Ook beschikbaar met jet-inhaler. Inhalatiepoeder Easyhaler 200 microg/dosis; 200 doses. Inhalatiepoeder Easyhaler 400 microg/dosis; 100 doses. Inhalatiepoeder Novolizer 200 microg; 200 doses. Inhalatiepoeder Novolizer 400 microg/dosis; 100 doses. Inhalatiepoeder in patroon Cyclocaps 200 microg, 400 microg, 800 microg). PULMICORT [AstraZeneca bv]. (Dosisaërosol CFK-vrij 50 microg/dosis; 120 doses. dr. J.C.C.M. in t Veen, dr. N.H. Chavannes, Het Astma Formularium, DOI 10.1007/978-90-313-8641-3, 2011 Bohn Stafleu van Loghum, onderdeel van Springer Media
90 Het Astma Formularium Dosisaërosol CFK-vrij Nebuhaler 50 microg/dosis; 120 doses. Dosisaërosol CFK-vrij 200 microg/dosis; 120 doses. Dosisaërosol CFK-vrij Nebuhaler 200 microg/dosis; 120 doses. Inhalatiepoeder Turbuhaler 100 microg/dosis; 200 doses. Inhalatiepoeder Turbuhaler 200 microg/dosis; 200 doses. Inhalatiepoeder Turbuhaler 400 microg/dosis; 50 doses, 200 doses. Inhalatievloeistof Respules 125 microg/ml; 2 ml. Inhalatievloeistof Respules 250 microg/ml; 2 ml. Inhalatievloeistof Respules 500 microg/ml; 2 ml) budesonide/formoterol: SYMBICORT [AstraZeneca bv] (Inhalatiepoeder Turbuhaler 100/6 ; 120 doses. Bevat per dosis formoterol(fumaraat) 6 microg, budesonide 100 microg. Inhalatiepoeder Turbuhaler 200/6 ; 120 doses. Bevat per dosis formoterol(fumaraat) 6 microg, budesonide 200 microg. Inhalatiepoeder Turbuhaler 400/12 ; 60 doses. Bevat per dosis formoterol(fumaraat) 12 microg, budesonide 400 microg.) ciclesonide: ALVESCO [Nycomed Nederland bv] (Dosisaërosol Inhalator 80 microg/dosis; 60 doses. Dosisaërosol Inhalator 160 microg/dosis; 60 doses. Dosisaërosol Aerochamber plus met mondstuk 160 microg/dosis; 60 doses) cromoglicinezuur: ALLERGOCROM COMOD NEUSSPRAY [Ursapharm Benelux bv] (di-na-zout) 9Neusspray 20 mg/ml; 15 ml. Per verstuiving 2,8 mg. Bevat NaEDTA). CROMOGLICINEZUUR NEUSSPRAY [Diverse fabrikanten] (di-na-zout) (Neusspray 20 mg/ml; 30 ml. Bevat conserveermiddelen benzalkoniumchloride en NaEDTA). LOMUSOL NEUSSPRAY [Sanofi- Aventis] (di-na-zout) (Neusspray 20 mg/ml; 26 ml. Per verstuiving 2,6 mg. Bevat conserveermiddelen benzalkoniumchloride en NaEDTA. Neusspray Forte 40 mg/ml; 22 ml. Per verstuiving 5 mg. Bevat conserveermiddelen benzalkoniumchloride en NaEDTA). PREVALIN [Chefaro Nederland bv] (di-na-zout) (Neusspray 20 mg/ml; 15 ml. Per verstuiving 2,6 mg. Bevat conserveermiddelen benzalkoniumchloride en NaEDTA. Neusspray Extra sterk 40 mg/ml; 15 ml. Bevat conserveermiddelen benzalkoniumchloride en NaEDTA). VIVIDRIN NEUSSPRAY [Tramedico bv] (di-na-zout) (Neusspray 20 mg/ml; 30 ml. Per verstuiving 2,5 mg. Bevat conserveermiddelen benzalkoniumchloride en NaEDTA) dexamethason: DEXAMETHASON CAPSULES FNA [formularium der Nederlandse Apothekers] (Capsule 10-40 mg. Oplopend
Geneesmiddelenoverzicht 91 met 5 mg (Capsulae dexamethasoni FNA). DEXAMETHASON INJECTIES/TABLETTEN [Diverse fabrikanten] (Tablet 0,5 mg, 1,5 mg. (di-na-fosfaat) (Injectievloeistof voor i.m., i.v., gelokaliseerde en s.c. injectie 5 mg/ml; ampul 1 ml. Conserveermiddelen: benzylalcohol en natriumbisulfiet. (als di-na-fosfaat) (Injectievloeistof voor uitsluitend i.v. gebruik 20 mg/ml; ampul 1 ml. Conserveermiddelen: benzylalcohol en natriummetabisulfiet). ORADEXON [Schering-Plough bv] (di-na-fosfaat) (Injectievloeistof voor i.m., i.v., gelokaliseerde en s.c. injectie 5 mg/ml; ampul 1 ml. Conserveermiddelen: methyl- en propylparahydroxybenzoaat) fluticason: FLIXOTIDE [GlaxoSmithKline bv] (propionaat) (Dosisaërosol CFK-vrij Inhalator 50 microg/dosis; 120 doses. Dosisaërosol CFK-vrij Volumatic 50 microg/dosis; 120 doses. Dosisaërosol CFK-vrij Inhalator 125 microg/dosis; 120 doses. Dosisaërosol CFK-vrij Volumatic 125 microg/dosis; 120 doses. Dosisaërosol CFK-vrij Inhalator 250 microg/dosis; 120 doses. Dosisaërosol CFK-vrij Volumatic 250 microg/dosis; 120 doses. Inhalatiepoeder Diskus 100 microg/dosis; 60 doses. Inhalatiepoeder Diskus 250 microg/dosis; 60 doses. Inhalatiepoeder Diskus 500 microg/dosis; 60 doses. Inhalatievloeistof Nebules 250 microg/ml; ampul 2 ml. Inhalatievloeistof Nebules 1000 microg/ml; ampul 2 ml) formoterol: ATIMOS [Chiesi Pharmaceuticals bv] (fumaraat) (Dosisaërosol CFK-vrij 12 microg/dosis; 100 doses). FORADIL [Novartis Pharma bv] (fumaraat) (Dosisaërosol CFK-vrij Inhalator 12 microg/dosis; 100 doses. Inhalatiepoeder in capsule 12 microg). FORMOTEROL INHALATIEPOEDER [Diverse fabrikanten] (fumaraat) (Inhalatiepoeder in capsule 12 microg; met inhalator. Inhalatiepoeder in capsule Cyclocaps 12 microg; met inhalator (Cyclohaler). Inhalatiepoeder Easyhaler 12 microg/ dosis; 120 doses. Inhalatiepoeder Novolizer 6 microg/dosis; 60 doses. Inhalatiepoeder Novolizer 12 microg/dosis; 60 doses). OXIS [AstraZeneca bv] (fumaraat) (Inhalatiepoeder Turbuhaler 6 microg/dosis; 60 doses. Inhalatiepoeder Turbuhaler 12 microg/dosis; 60 doses) ipratropium: ATROVENT [Boehringer Ingelheim bv] (bromide) (Capsule Inhalette 40 microg. Dosisaërosol 20 microg/dosis; 200 doses. Inhalatievloeistof Unit Dose 125 microg/ml; flacon 2 ml. Inhalatievloeistof Unit Dose 250 microg/ml; flacon 2 ml. IPRATROPIUM INHALATIEPOEDER [Diverse fabrikanten] (bro-
92 Het Astma Formularium mide) (Capsule Cyclocaps 40 microg. IPRAXA [IVAX Farma bv] (bromide) (Inhalatievloeistof Steri-Neb 250 microg/ml; flacon 1ml,2ml) montelukast: SINGULAIR [Merck Sharp & Dohme bv] (Na-zout) (Granulaat 4 mg; in sachet. Kauwtablet 4 mg, 5 mg. De kauwtabletten bevatten aspartaam respectievelijk overeenkomend met 0,674 mg en 0,842 mg fenylalanine. Tablet 10 mg) nedocromil: TILAVIST [Sanofi-Aventis] (di-na-zout) (Oogdruppels (2%) 20 mg/ml; 5 ml. Conserveermiddel: benzalkoniumchloride) omalizumab: XOLAIR [Novartis Pharma bv] (Poeder voor injectievloeistof 150 mg. Met solvens. Bevat na reconstitutie 125 mg/ ml; 1,2 ml) prednisolon: DI-ADRESON-F AQUOSUM [Schering-Plough bv] (Na-succinaat) (Poeder voor injectievloeistof voor i.m., i.v., gelokaliseerde en s.c. injectie en rectale toediening 25 mg; met solvens (gedestilleerd water) 1 ml). PREDNISOLON CAPSULES/ DRANK FNA [formularium der Nederlandse Apothekers] (Capsule 10-75 mg. Oplopend met 5 mg (Capsulae prednisoloni FNA). (als di-na-fosfaat) (Drank 1 mg/ml, 5 mg/ml. Conserveermiddel: methylparahydroxybenzoaat (Mixtura prednisoloni FNA). PREDNISOLON INJECTIES/TABLETTEN [Diverse fabrikanten] (Tablet 5 mg, 20 mg, 30 mg). (Na-succinaat) (Poeder voor injectievloeistof voor i.m., i.v., gelokaliseerde en s.c. injectie 25 mg) salbutamol: AIROMIR [IVAX Farma bv] (als sulfaat) (Dosisaërosol CFK-vrij 100 microg/dosis; 200 doses. Dosisaërosol CFK-vrij Autohaler 100 microg/dosis; 200 doses). SALBUTAMOL INHA- LATIE [Diverse fabrikanten] (als sulfaat) (Dosisaërosol CFK-vrij 100 microg/dosis; 200 doses. Inhalatiepoeder Novolizer 100 microg/dosis; 200 doses. Inhalatiepoeder in patroon Cyclocaps 200 microg, 400 microg. Inhalatievloeistof 5 mg/ml; 30 ml. De inhalatievloeistof bevat conserveermiddel benzalkoniumchloride 100 microg/ml). SALBUTAMOL REDIHALER [TEVA] (dosisaërosol 100 microg/dosis; suspencie 100 micro/dosis). VENTOLIN INHALATIE [GlaxoSmithKline bv] (als sulfaat) (Dosisaërosol CFK-vrij Inhalator 100 microg/dosis; 200 doses. Dosisaërosol CFK-vrij Babyhaler 100 microg/dosis; 200 doses. Dosisaërosol CFK-vrij Volumatic 100 microg/dosis; 200 doses. Inhalatiepoeder Diskus 200 microg/dosis; 60 doses. Inhalatievloeistof Nebules 1 mg/ml; 2,5 ml. Inhalatievloeistof Nebules
Geneesmiddelenoverzicht 93 2 mg/ml; 2,5 ml. Inhalatievloeistof 5 mg/ml; 20 ml. De inhalatievloeistof bevat conserveermiddel benzalkoniumchloride 100 microg/ml) salmeterol: SEREVENT [GlaxoSmithKline bv] (als xinafoaat) (Dosisaërosol CFK-vrij Inhalator 25 microg/dosis; 120 doses. Dosisaërosol Volumatic 25 microg/dosis; 120 doses. Inhalatiepoeder Diskus 50 microg/dosis; 60 doses) sameterol/fluticason: SERETIDE [GlaxoSmithKline bv] (Dosisaërosol CFK-vrij 25/50 Inhalator ; 120 doses. Bevat per dosis: salmeterol (als xinafoaat) 25 microg, fluticason(propionaat) 50 microg. Dosisaërosol CFK-vrij 25/125 Inhalator ; 120 doses. Bevat per dosis: salmeterol (als xinafoaat) 25 microg, fluticason(propionaat) 125 microg. Dosisaërosol CFK-vrij 25/250 Inhalator ; 120 doses. Bevat per dosis: salmeterol (als xinafoaat) 25 microg, fluticason(propionaat) 250 microg. Inhalatiepoeder 50/ 100 Diskus ; 60 doses. Bevat per dosis: salmeterol (als xinafoaat) 50 microg, fluticason(propionaat) 100 microg. Inhalatiepoeder 50/250 Diskus ; 60 doses. Bevat per dosis: salmeterol (als xinafoaat) 50 microg, fluticason(propionaat) 250 microg. Inhalatiepoeder 50/500 Diskus ; 60 doses. Bevat per dosis: salmeterol (als xinafoaat) 50 microg, fluticason(propionaat) 500 microg) terbutaline: BRICANYL [AstraZeneca bv] (sulfaat) (Inhalatiepoeder Turbuhaler 250 microg/dosis; 200 doses. Inhalatiepoeder Turbuhaler 500 microg/dosis; 200 doses) theofylline: THEOFYLLINE KLYSMA FNA [formularium der Nederlandse Apothekers] (als megluminezout) (Klysma 10 mg/ml; flacon 10 ml. Klysma 30 mg/ml; flacon 10 ml. Klysma 50 mg/ml; flacon 10 ml. (Clysma theophyllini). THEOLAIR [3M Pharma Nederland bv] (Tablet met gereguleerde afgifte Retard 175 mg, 250 mg, 350 mg) tiotropium: SPIRIVA [Diverse fabrikanten] (als bromide monohydraat) (Inhalatiepoeder in capsule 18 microg. Eventueel afgeleverd met Handihaler. Inhalatievloeistof Respimat 2,5 microg/ dosis; 60 doses